News

The grant will allow the company to progress OCD155 through pre-clinical development towards clinical trials and to further unravel the mechanism-of-action, which will be done in a Dutch-Danish-German-Swiss

Around 54 male patients will be enrolled in the trial, which is designed to evaluate the pharmacokinetics (PK), efficacy, and safety of rVIIa-FP in these patients who have

If etelcalcetide gets approval, it will be the first calcimimetic agent that can be administered intravenously at the end of the dialysis session. Etelcalcetide is a new calcimimetic

The new formula is comprised of clinically proven ingredients for immune protection including: EpiCor, a specialized yeast fermentate, Lactobacillus GG, the number one studied probiotic strain backed by

Study 332 showed that FYCOMPA, when used as adjunctive therapy in the treatment of PGTC seizures in patients age 12 and older, reduced median percent in seizure frequency

Market surveys clearly indicate that Brazil is one of the fastest growing pharmaceutical markets globally, with its huge population of more than 200 million, an investment friendly environment,

Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. This black particle,

Canada-based Portage Biotech holds 54% equity interest in Biohaven Pharmaceutical Holding Company. With the completion of FDA review, Biohaven now plans to immediately proceed with a Phase I

HLD-200 uses Ironshore’s drug delivery platform, DELEXIS, to enable nighttime dosing of these patients. The multicenter, double-blind, randomized, placebo-controlled, parallel group Phase III trial (AHEAD) is designed to